Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ianalumab versus placebo in adults with Sjögren's disease
NL-OMON61680Phase 3Not yet recruiting
- Sponsor
- Novartis
- Start
- Oct 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Sjögren's syndrome comparing Ianalumab with Placebo (2 arms). Primary endpoint: Change from baseline in SSSD oral dryness score at Week 52. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
ianalumab
03
Conditions
Sjögren's syndrome
Beyond the preview
Go deeper on NL-OMON61680.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61680.